A recent study using S-2-(4-isothiocyanatobenzyl)-1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA) as the 64Cu chelator labeled with AC133 monoclonal antibody (64Cu-NOTA-AC133 mAb) for PET and AC133 mAb-based near-infrared fluorescence molecular tomography has indicated CSC monitoring through imaging CD133 expression of stem and progenitor cells in many types of malignant tumors of human origin [142,143]. The gene discussed is PROM1; the disease is cancer.